tiprankstipranks
Trending News
More News >

Fate Therapeutics price target lowered to $2 from $10 at Barclays

Barclays lowered the firm’s price target on Fate Therapeutics (FATE) to $2 from $10 and keeps an Overweight rating on the shares following the Q1 report. The firm has “derisked” Fate’s model.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1